Patent Portfolio Valuation

Three primary valuation approaches are used for patents, each appropriate in different contexts: INCOME APPROACH: DISCOUNTED CASH FLOW (DCF): project future cash flows from the patent (licensing revenue; royalties; avoided costs) over the remaining patent life; discount at an appropriate risk-adjusted rate; the most rigorous but requires significant assumptions about future market size, market share, royalty rates, and growth; best for patents with established licensing programs or clear product revenue attribution; RELIEF-FROM-ROYALTY METHOD: the value of a patent equals the present value of the royalty payments the owner avoids by owning the patent (vs. having to license it from a third party); requires identifying a market royalty rate for comparable technologies; widely used in accounting fair value determinations (ASC 805; IFRS 3); common in litigation damages analysis; excess earnings method: attribute the portfolio's excess earnings (above a fair return on tangible assets) to the patent portfolio; MARKET APPROACH: COMPARABLE LICENSE ANALYSIS: compare the patent to similar patents that have been licensed; look at royalty rates in comparable agreements (industry; technology; exclusivity; geographic scope); Georgia-Pacific factors provide a structured framework for comparable license analysis; PATENT TRANSACTION DATABASES: use databases of patent sale and purchase transactions to benchmark portfolio value; difficult in practice because most transactions are private; Royalty Range; ktMINE; IPIQ; provide some transaction data; COST APPROACH: REPRODUCTION COST: what would it cost to recreate the patent (research, development, prosecution costs) from scratch?; REPLACEMENT COST: what would it cost to develop alternative technology that provides the same function?; most appropriate for early-stage patents before commercial application is established; tends to undervalue patents that have commercial success; used as a floor value or for insurance purposes.

The Georgia-Pacific factors are the standard framework for reasonable royalty analysis in US patent litigation: SOURCE: Georgia-Pacific Corp. v. US Plywood Corp. (S.D.N.Y. 1970): the court articulated 15 factors for determining a 'reasonable royalty' as patent damages; THE HYPOTHETICAL NEGOTIATION: Georgia-Pacific asks: what royalty would the parties have agreed to in a hypothetical arm's-length negotiation immediately before infringement began, with full knowledge that the patent is valid and infringed?; THE 15 FACTORS: (1) royalties patentee receives for licensing the patent in suit; (2) rates the licensee pays for comparable patents; (3) nature/scope of the license (exclusive vs. non-exclusive; field; geography); (4) patentee's established policy not to license or to license selectively; (5) commercial relationship between patentee and infringer (competitors vs. non-competitors); (6) effect of selling the patented specialty in promoting sales of other products; (7) duration of the patent and term of the license; (8) established profitability of the patented product; (9) utility/advantages over prior inventions; (10) nature of the patented invention (commercial embodiment; value; extent); (11) infringer's extent of use of the invention and value of that use; (12) portion of profit/selling price customary in the business for similar inventions; (13) portion of realizable profit attributable to the patent (vs. other elements); (14) opinion testimony of qualified experts; (15) result of a hypothetical negotiation between a licensor willing to grant and licensee willing to accept a license; APPORTIONMENT: damages must be apportioned to the patent's contribution to the entire product; SMALLEST SALEABLE PATENT-PRACTICING UNIT (SSPPU): royalty base should be the smallest component that practices the patent, not the entire product; ENTIRE MARKET VALUE RULE (EMVR): the full product can be the royalty base ONLY if the patent is the basis for customer demand for the entire product; difficult to satisfy in practice.

M&A patent valuation requires both legal and financial due diligence: PRE-ACQUISITION PATENT DUE DILIGENCE: OWNERSHIP VERIFICATION: confirm the target actually owns the patents (all inventors assigned; assignments recorded at USPTO); check for Bayh-Dole restrictions (government license; march-in); confirm no third-party claims on the patents; VALIDITY ASSESSMENT: prior art search for key patents; IPR petition risk; claim scope analysis; prosecution history review; any pending challenges; FREEDOM TO OPERATE: do the target's products infringe third-party patents?; are there blocking patents that limit the target's business?; LICENSING OBLIGATIONS: existing licenses granted to others (inbound and outbound); exclusive licenses that limit the acquirer's use; sublicensing rights; ENCUMBRANCES: security interests in patents (recorded at USPTO); pending litigation; covenant-not-to-sue agreements; POST-ACQUISITION ACCOUNTING (ASC 805): purchase price allocation (PPA) requires assigning fair value to intangible assets including patents; the relief-from-royalty method is most commonly used for accounting fair value; identified patents are amortized over their useful life; PATENT PORTFOLIO PREMIUM: studies show patents contribute 20-40% of M&A acquisition value in IP-intensive sectors (semiconductors; pharmaceuticals; software); DISCOUNTING FOR RISKS: remaining term (shorter = lower value); claim breadth (narrow claims = lower value); validity risk (high prior art = discount); pending litigation = discount or escrow; geographic coverage (US-only vs. global = lower for domestic-only); STRATEGIC VALUE: blocking position vs. competitor; freedom to operate value; defensive portfolio value (mutual assured destruction); licensing revenue potential; JOINT VENTURE IP: IP contributed to joint ventures may have complex ownership; review JV agreements carefully.

Patent value is driven by a combination of legal strength and commercial applicability: VALUE DRIVERS (FACTORS THAT INCREASE PATENT VALUE): (1) CLAIM BREADTH: broad independent claims covering multiple implementations are more valuable; narrow claims easier to design around; (2) REMAINING TERM: patents near expiration have lower value; newly issued patents (or patents with continuations) have higher value; (3) COMMERCIAL RELEVANCE: patents that block a significant revenue stream are most valuable; patent on the dominant platform/standard; (4) VALIDITY STRENGTH: strong prosecution history; limited prior art; claims survived reexamination or IPR; (5) CLAIM DIVERSITY: method + apparatus + system + CRM claims provide multiple assertion angles; (6) CONTINUATION CHAIN: pending continuations allow new claims; ongoing presence in technology space; (7) GEOGRAPHIC COVERAGE: US + EP + CN + JP + KR coverage commands premium over US-only; (8) PROSECUTION HISTORY QUALITY: clean prosecution history without excessive narrowing; limited arguments that could create estoppel; (9) PORTFOLIO SIZE AND DEPTH: multiple patents covering the same technology from different angles; (10) STANDARDS RELEVANCE: if the patent is essential to an industry standard, it commands significant licensing value (though FRAND constraints apply); VALUE REDUCERS: imminent expiration; narrow claims (single embodiment); weak prosecution history; prior art challenges pending; limited geographic coverage; continuation chain expiring; design-around feasibility; rapidly evolving technology (patent obsolete before term ends); post-Amgen enablement concerns (for biotech genus claims); strong prior art found by independent search; inconsistent prosecution history; assignment chain problems; maintenance fees not paid (patent lapsed).

Standards-essential patent (SEP) valuation is a specialized area with distinct constraints: THE FRAND COMMITMENT: when a company discloses a patent as potentially essential to a standard (in the SSO's patent policy), it typically commits to license on Fair, Reasonable, and Non-Discriminatory (FRAND) terms; the FRAND commitment is contractual (through the SSO); enforced in courts; WHAT FRAND DOES NOT DEFINE: FRAND does not specify a rate — it is a constraint on the licensing process; courts and arbitrators must determine what is FRAND in specific cases; FRAND VALUATION METHODOLOGIES: (1) TOP-DOWN APPROACH: start with the total aggregate royalty for all SEPs covering the standard; divide by the total number of truly essential patents; each SEP gets a proportionate share; avoids royalty stacking; problem: determining 'total SEP count' and 'true essentiality' is difficult; (2) COMPARABLE LICENSE APPROACH: look at what actual FRAND licenses have been signed for similar technologies; courts prefer this where comparables exist (Ericsson v. D-Link; TCL v. Ericsson; Unwired Planet v. Huawei); problem: most licenses are confidential; determination of 'comparable' is disputed; (3) INCREMENTAL VALUE APPROACH: what is the incremental value of the patented feature over the next-best non-infringing alternative?; focused on the technical contribution; (4) PROPORTIONALITY APPROACH: compare the SEP holder's share of truly essential patents against the total SEP landscape; ANTI-HOLDUP PRINCIPLE: FRAND rates should be based on the value of the technology BEFORE the standard is set; not on the enhanced value that comes from being incorporated into an adopted standard (holdup); courts in the UK, Germany, and US have all developed FRAND rate-setting frameworks; ERICSSON v. D-LINK NETWORKS (Fed. Cir. 2014): Georgia-Pacific factors apply to SEPs; however, courts must carefully account for: (a) the hold-up risk (incremental value; not standard adoption value); (b) royalty stacking risk (many SEPs from many holders; aggregate royalty must be reasonable).